Membrane-drug interactions studied using model membrane systems

Saudi Journal of Biological Sciences

Volumn 22, Issue 6, 2015, Pages 714-718

  Knobloch, Jacqueline ^a   Suhendro, Daniel K ^a   Zieleniecki, Julius L ^a   Shapter, Joseph G ^a   Köper, Ingo ^a  

^a Flinders University ^*  (Australia)

Author keywords

Drug membrane interaction; Drugs; Model membranes; Review

Indexed keywords

EID: 84945453858     PISSN: 1319562X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.sjbs.2015.03.007     Document Type: Article

References (33)

1. Ambike A., et al. Interaction of self-assembled squalenoyl gemcitabine nanoparticles with phospholipid-cholesterol monolayers mimicking a biomembrane. Langmuir 2011, 27(8):4891-4899.
2. Ashrafuzzaman M., et al. Chemotherapy drugs form ion pores in membranes due to physical interactions with lipids. Chem. Biol. Drug. Des. 2012, 80(6):992-1002.
3. Baciu M., et al. Degradative transport of cationic amphiphilic drugs across phospholipid bilayers. Philos. Trans. R. Soc. A: Math. Phys. Eng. Sci. 1847, 2006(364):2597-2614.
4. Braunagel J., Junghans A., Köper I. Membrane-based sensing approaches. Aust. J. Chem. 2011, 64(1):54-61.
5. Castellana E.T., Cremer P.S. Solid supported lipid bilayers: from biophysical studies to sensor design. Surf. Sci. Rep. 2006, 61(10):429-444.
6. Chan Y.H.M., Boxer S.G. Model membrane systems and their applications. Curr. Opin. Chem. Biol. 2007, 11:581-587.
7. Chang W.K., et al. Characterization of antimicrobial peptide activity by electrochemical impedance spectroscopy. Biochim. Biophys. Acta 2008, 1778(10):2430-2436.
8. Cohen P. Protein kinases - the major drug targets of the twenty-first century?. Nat. Rev. Drug Discov. 2002, 1(4):309-315.
9. Domenech O., et al. Interactions of oritavancin, a new lipoglycopeptide derived from vancomycin, with phospholipid bilayers: effect on membrane permeability and nanoscale lipid membrane organization. Biochim. Biophys. Acta 2009, 1788(9):1832-1840.
10. Dowhan W. Molecular basis for membrane phospholipid diversity: why are there so many lipids?. Annu. Rev. Biochem. 1997, 66:199-232.
11. Escriba P.V., et al. Membranes: a meeting point for lipids, proteins and therapies. J. Cell. Mol. Med. 2008, 12(3):829-875.
12. Fernandez D.I., et al. Interactions of a synthetic Leu-Lys-rich antimicrobial peptide with phospholipid bilayers. Eur. Biophys. J. 2011, 40(4):471-480.
13. Junghans A., et al. Protein-lipid interactions at the air-water interface. Langmuir 2010, 26(14):12049-12053.
14. Köper I. Insulating tethered bilayer lipid membranes to study membrane proteins. Mol. Biosyst. 2007, 651-657.
15. McLure J.A., Miners J.O., Birkett D.J. Nonspecific binding of drugs to human liver microsomes. Br. J. Clin. Pharmacol. 2000, 49(5):453-461.
16. Michot J.M., et al. Influence of efflux transporters on the accumulation and efflux of four quinolones (ciprofloxacin, levofloxacin, garenoxacin, and moxifloxacin) in J774 macrophages. Antimicrob. Agents Chemother. 2005, 49(6):2429-2437.
17. Nagar S., Korzekwa K. Commentary: nonspecific protein binding versus membrane partitioning: it is not just semantics. Drug Metab. Dispos. 2012, 40(9):1649-1652.
18. Naumann R., et al. Tethered lipid bilayers on ultraflat gold surfaces. Langmuir 2003, 19:5435-5443.
19. Nunes C., et al. NSAIDs interactions with membranes: a biophysical approach. Langmuir 2011, 27(17):10847-10858.
20. Nussio M.R., et al. Characterisation of the binding of cationic amphiphilic drugs to phospholipid bilayers using surface plasmon resonance. ChemMedChem 2007, 2(3):366-373.
21. Nussio M.R., et al. Kinetics membrane disruption due to drug interactions of chlorpromazine hydrochloride. Langmuir 2008, 25(2):1086-1090.
22. Olson F., et al. Preparation of liposomes of defined size distribution by extrusion through polycarbonate membranes. Biochim. Biophys. Acta 1979, 557(1):9-23.
23. Peetla C., Labhasetwar V. Biophysical characterization of nanoparticle-endothelial model cell membrane interactions. Mol. Pharmaceutics 2008, 5(3):418-429.
24. Peetla C., Labhasetwar V. Effect of molecular structure of cationic surfactants on biophysical interactions of surfactant-modified nanoparticles with a model membrane and cellular uptake. Langmuir 2009, 25(4):2369-2377.
25. Peetla C., Stine A., Labhasetwar V. Biophysical interactions with model lipid membranes: applications in drug discovery and drug delivery. Mol. Pharmaceutics 2009, 6(5):1264-1276.
26. Peetla C., et al. Drug resistance in breast cancer cells: biophysical characterization of and doxorubicin interactions with membrane lipids. Mol. Pharmaceutics 2010, 7(6):2334-2348.
27. Perozo E., et al. Physical principles underlying the transduction of bilayer deformation forces during mechanosensitive channel gating. Nat. Struct. Biol. 2002, 9(9):696-703.
28. Pinheiro M., et al. The influence of Rifabutin on human and bacterial membrane models: implications for its mechanism of action. J. Phys. Chem. B 2013, 117(20):6187-6193.
29. Sackmann E. Supported membranes: scientific and practical applications. Science 1996, 271:43-48.
30. Smith D.A., Di L., Kerns E.H. The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery. Nat. Rev. Drug Discov. 2010, 9(12):929-939.
31. Stetter F.W., Hugel T. The nanomechanical properties of lipid membranes are significantly influenced by the presence of ethanol. Biophys. J. 2013, 104(5):1049-1055.
32. Vogel N., Zieleniecki J., Koper I. As flat as it gets: ultrasmooth surfaces from template-stripping procedures. Nanoscale 2012, 4(13):3820-3832.
33. Yildirim M.A., et al. Drug-target network. Nat. Biotechnol. 2007, 25(10):1119-1126.